Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 56

Sort by

Sort Order Select

Journal Articles

Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma

Blood (2019) 134 (Supplement_1): 1904.

https://doi.org/10.1182/blood-2019-131478

Published: 2019

Journal Articles

Blockade of CD95/CD95L Death Signaling Enhances CAR T Cell Persistence and Antitumor Efficacy

Bailin He, PhD, Lei Wang, MD, Brigitte Neuber, Anita Schmitt, MD, Niclas Kneisel, PhD, Thomas Hoeger, PhD, Carsten Mueller-Tidow, MD, Michael Schmitt, MD, Susanne Hofmann, MD

Blood (2019) 134 (Supplement_1): 3226.

https://doi.org/10.1182/blood-2019-122833

Published: 2019

Journal Articles

Ibrutinib Treatment in CLL Patients Improves T Cell Function and Blinatumomab Redirected Cytotoxicity

Meixiao Long, MD, Erich Williams, Clara Berard, Carolyn Cheney, BS, Eileen Hu, BS, Seema A. Bhat, MD, Kerry A. Rogers, MD, Jennifer Woyach, MD, Natarajan Muthusamy, DVM,PhD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 1049.

https://doi.org/10.1182/blood-2019-125417

Published: 2019

Journal Articles

Efficacy and Safety of Ixazomib-Dexamethasone, Ixazomib-Cyclophosphamide-Dexamethasone, Ixazomib-Thalidomide-Dexamethasone and Ixazomib-Bendamustine-Dexamethasone for Elderly Newly Diagnosed Multiple Myeloma (NDMM) Patients: Analysis of the Phase II Randomized Unito-EMN10 Study

Blood (2019) 134 (Supplement_1): 3195.

https://doi.org/10.1182/blood-2019-124388

Published: 2019

Journal Articles

Dimethyl Oxalyl Glycine a Prolyl Hydroxylase Inhibitor Decreases Early Gastrointestinal Gvhd Via Two Independent Pathways of Apoptosis after Allogeneic Hematopoietic Cell Transplantation

Reena Kumari, PhD, Senthilnathan Palaniyandi, PhD, Ethan Strattan, BS, Sabarinath Venniyil Radhakrishnan, MBBS, MD, Gerhard Carl Hildebrandt, MD

Blood (2018) 132 (Supplement 1): 3317.

https://doi.org/10.1182/blood-2018-99-116245

Published: 2018

Journal Articles

Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia

Amanda M. Li, MD, George E Hucks, Amanda M. Dinofia, MD, Alix E. Seif, MD, David T Teachey, MD, Diane Baniewicz, Colleen Callahan, Christina Fasano, Beth McBride, Vanessa Gonzalez, Farzana Nazimuddin, MS, David L. Porter, MD, Simon F Lacey, PhD BS, Carl H June, MD, Stephan A. Grupp, MD PhD, Shannon L. Maude, MD PhD

Blood (2018) 132 (Supplement 1): 556.

https://doi.org/10.1182/blood-2018-99-112572

Published: 2018

Journal Articles

Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies

Meletios A. Dimopoulos, Jacob Laubach, MD, Maria Asuncion Echeveste Gutierrez, Norbert Grząśko, Craig C Hofmeister, MDMPH, Jesus F. San Miguel, MD, Shaji K Kumar, MD, Vickie Lu, PhD, Zhaoyang Teng, PhD, Guohui Liu, PhD, Catriona Byrne, RN, Deborah Berg, RN, MSN, Richard Labotka, MD MS, Helgi van de Velde, MD PhD, Paul G Richardson, MD

Blood (2017) 130 (Supplement 1): 902.

https://doi.org/10.1182/blood.V130.Suppl_1.902.902

Published: 2017

Journal Articles

Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism

Meixiao Long, MD PhD, Kyle A. Beckwith, PhD, Priscilla Do, BS, Mundy L Bethany, PhD, Gordon Gordon, Amy M. Lehman, MAS, Kami J. Maddocks, MD, Carolyn Cheney, BS, Jeffrey Jones, MD MPH, Leslie A. Andritsos, MD, Farrukh T. Awan, Joseph A. Fraietta, PhD, Carl H June, MD, Marcela V. Maus, MDPhD, Jennifer A. Woyach, MD, Michael A. Caligiuri, MD, Amy J. Johnson, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD

Blood (2016) 128 (22): 3238.

https://doi.org/10.1182/blood.V128.22.3238.3238

Published: 2016

Journal Articles

Phase 2 Study of the All-Oral Combination of Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Shaji Kumar, MD, Norbert Grzasko, MD PhD, Sosana Delimpasi, MD, Wieslaw W Jędrzejczak, MD, Sebastian Grosicki, MD PhD, Marie-Christine Kyrtsonis, MD PhD, Andrew Spencer, Neeraj Gupta, PhD, Zhaoyang Teng, PhD, Catriona Byrne, RN, Richard Labotka, MD MS, Meletios A Dimopoulos

Blood (2016) 128 (22): 3327.

https://doi.org/10.1182/blood.V128.22.3327.3327

Published: 2016

Journal Articles

Direct Comparison of In Vivo Fate of Second and Third-Generation CD19-Specific Chimeric Antigen Receptor (CAR)-T Cells in Patients with B-Cell Lymphoma: Reversal of Toxicity from Tonic Signaling

Diogo Gomes da Silva, Malini Mukherjee, Madhuwanti Srinivasan, Olga Dakhova, PhD, Hao Liu, PhD, Bambi Grilley, Adrian P. Gee, PhD, Sattva S. Neelapu, MD, Cliona M. Rooney, PhD, Helen E Heslop, MD DSc (Hon), Barbara Savoldo, MD PhD, Gianpietro Dotti, MD, Malcolm K. Brenner, MD PhD, Maksim Mamonkin, PhD, Carlos A. Ramos, MD

Blood (2016) 128 (22): 1851.

https://doi.org/10.1182/blood.V128.22.1851.1851

Published: 2016

Journal Articles

PD-1 Signaling Has a Critical Role in Maintaining Regulatory T Cell Homeostasis; Implication for Treg Depletion Therapy By PD-1 Blockade

Takeru Asano, MD, Yuriko Kishi, Yusuke Meguri, MD, Takanori Yoshioka, MD, Miki Iwamoto, Yoshinobu Maeda, MD PhD, Hideo Yagita, PhD, Mitsune Tanimoto, MD PhD, John Koreth, MBBS, DPhil, Jerome Ritz, MD, Ken-Ichi Matsuoka, MDPhD

Blood (2015) 126 (23): 848.

https://doi.org/10.1182/blood.V126.23.848.848

Published: 2015

Journal Articles

Single Cell RNA seq for Analysis of Cell Fate Decisions

H. Leighton Grimes, PhD, Singh Harinder, PhD, Andre Olsson, PhD, Nathan Salomonis, PhD, Bruce J. Aronow, PhD, Viren Chaudhry, PhD

Blood (2015) 126 (23): SCI-20.

https://doi.org/10.1182/blood.V126.23.SCI-20.SCI-20

Published: 2015

Journal Articles

High Incidence of Induction Failure and Poor Outcome in Patients with Gamma Delta T Cell Acute Lymphoblastic Leukemia

Mari H Dallas, MD, Paul Thomas, PhD, John Choi, William E. Evans, PharmD, Hiroto Inaba, MD PhD, Sima Jeha, MD, Ching-Hon Pui, MD

Blood (2015) 126 (23): 1421.

https://doi.org/10.1182/blood.V126.23.1421.1421

Published: 2015

Journal Articles

Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070)

Meletios A. Dimopoulos, Sebastian Grosicki, MD PhD, Wieslaw W Jedrzejczak, MDPhD, Hareth Nahi, Astrid Gruber, MD PhD, Markus Hansson, Catriona Byrne, RN, Richard Labotka, MD MS, Ai-Min Hui, MD PhD, Zhaoyang Teng, PhD, Norbert Grzasko, MD PhD

Blood (2015) 126 (23): 26.

https://doi.org/10.1182/blood.V126.23.26.26

Published: 2015

Journal Articles

Functional and Molecular Characterization of Serial Killer CAR+ T Cells Demonstrates Adaptive Modification of Fate and Behavior Based on Tumor Cell Density

Navin Varadarajan, PhD, Laurence JN Cooper, MD PhD, Liadi Ivan, Harjeet Singh, PhD, Badrinath Roysam, Romain Gabrielle, Merouane Amin

Blood (2014) 124 (21): 658.

https://doi.org/10.1182/blood.V124.21.658.658

Published: 2014

Journal Articles

Excessively High-Affinity Single-Chain Fragment Variable Region in a Chimeric Antigen Receptor Can Counteract T-Cell Proliferation

Keisuke Watanabe, MD, Seitaro Terakura, MD PhD, Susumu Uchiyama, PhD, Anton C. Martens, PhD, Tom van Meerten, PhD, Hitoshi Kiyoi, MD PhD, Tetsuya Nishida, MD PhD, Tomoki Naoe, MDPhD, Makoto Murata, MD PhD

Blood (2014) 124 (21): 4799.

https://doi.org/10.1182/blood.V124.21.4799.4799

Published: 2014

Journal Articles

Distinct Signaling By Chimeric Antigen Receptors (CARs) Containing CD28 Signaling Domain Versus 4-1BB In Primary Human T Cells

Omkar Uday Kawalekar, MS, BS, Avery D. Posey, Jr., Joseph Fraietta, Jihyun Lee, John Scholler, Yangbing Zhao, Carl H. June, MD

Blood (2013) 122 (21): 2902.

https://doi.org/10.1182/blood.V122.21.2902.2902

Published: 2013

Journal Articles

Perforin Is Important For Both CD4+ and CD8+ T Cell-Mediated Graft-Versus-Tumor Effect But Plays Differential Roles In CD4+ and CD8+ T Cell Expansion After Allogeneic Transplantation

Nicholas Leigh, Guanglin Bian, PhD, Wei Du, George L. Chen, MD, Hong Liu, MD, PhD, Philip L. McCarthy, Jr., MD, Xuefang Cao, PhD

Blood (2013) 122 (21): 3255.

https://doi.org/10.1182/blood.V122.21.3255.3255

Published: 2013

Journal Articles

Absence of STAT1 Signaling in Host Hematopoietic Cells Leads to Enhanced Gvhd Induction and Involves Increased Expression of MHC Class II and Reduced PD-L1 Expression on Dendritic Cells,

Caisheng Lu, PhD, Huihui Ma, M.D., Ph.D., Ailing Liu, PhD, MeiHua Jin, PhD, Shirong Li, PhD, Suzanne Lentzsch, MD, PhD, Markus Y. Mapara, MD, PhD

Blood (2011) 118 (21): 4026.

https://doi.org/10.1182/blood.V118.21.4026.4026

Published: 2011

Journal Articles

Intrinsic and Estrinsic Mechanism Contributes to Maintain the JAK/STAT Pathway Aberrantly Activated in T-Type Large Granular Lymphocyte Leukemia

Renato Zambello, Antonella Teramo, Cristina Gattazzo, Francesca Passeri, Albana Lico, Giulia Tasca, Anna Cabrelle, Federica Frezzato, Veronica Martini, Valentina Trimarco, Tamara Berno, Elisa Boscaro, Monica Facco, Livio Trentin, Gianpietro Semenzato, MD

Blood (2011) 118 (21): 1375.

https://doi.org/10.1182/blood.V118.21.1375.1375

Published: 2011

NARROW

Phase 2 Trial of Ixazomib, Cyclophosphamide and Dexamethasone in Relapsed Multiple Myeloma

Blockade of CD95/CD95L Death Signaling Enhances CAR T Cell Persistence and Antitumor Efficacy

Ibrutinib Treatment in CLL Patients Improves T Cell Function and Blinatumomab Redirected Cytotoxicity

Efficacy and Safety of Ixazomib-Dexamethasone, Ixazomib-Cyclophosphamide-Dexamethasone, Ixazomib-Thalidomide-Dexamethasone and Ixazomib-Bendamustine-Dexamethasone for Elderly Newly Diagnosed Multiple Myeloma (NDMM) Patients: Analysis of the Phase II Randomized Unito-EMN10 Study

Dimethyl Oxalyl Glycine a Prolyl Hydroxylase Inhibitor Decreases Early Gastrointestinal Gvhd Via Two Independent Pathways of Apoptosis after Allogeneic Hematopoietic Cell Transplantation

Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia

Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies

Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism

Phase 2 Study of the All-Oral Combination of Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Direct Comparison of In Vivo Fate of Second and Third-Generation CD19-Specific Chimeric Antigen Receptor (CAR)-T Cells in Patients with B-Cell Lymphoma: Reversal of Toxicity from Tonic Signaling

PD-1 Signaling Has a Critical Role in Maintaining Regulatory T Cell Homeostasis; Implication for Treg Depletion Therapy By PD-1 Blockade

Single Cell RNA seq for Analysis of Cell Fate Decisions

High Incidence of Induction Failure and Poor Outcome in Patients with Gamma Delta T Cell Acute Lymphoblastic Leukemia

Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070)

Functional and Molecular Characterization of Serial Killer CAR+ T Cells Demonstrates Adaptive Modification of Fate and Behavior Based on Tumor Cell Density

Excessively High-Affinity Single-Chain Fragment Variable Region in a Chimeric Antigen Receptor Can Counteract T-Cell Proliferation

Distinct Signaling By Chimeric Antigen Receptors (CARs) Containing CD28 Signaling Domain Versus 4-1BB In Primary Human T Cells

Perforin Is Important For Both CD4+ and CD8+ T Cell-Mediated Graft-Versus-Tumor Effect But Plays Differential Roles In CD4+ and CD8+ T Cell Expansion After Allogeneic Transplantation

Absence of STAT1 Signaling in Host Hematopoietic Cells Leads to Enhanced Gvhd Induction and Involves Increased Expression of MHC Class II and Reduced PD-L1 Expression on Dendritic Cells,

Intrinsic and Estrinsic Mechanism Contributes to Maintain the JAK/STAT Pathway Aberrantly Activated in T-Type Large Granular Lymphocyte Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only